$27M Raised To Redefine A $678B Industry
AJNA BioSciences is a clinical-stage biotech company developing botanical drugs for Autism, Anxiety, and PTSD. With four drug candidates — and our first drug candidate authorized to begin Phase 2 clinical trials in pediatrics and adults — we are developing full-spectrum cannabinoid and psilocybin-based pharmaceuticals to address unmet needs
Invest Today
This Reg CF offering is made available through StartEngine Primary, LLC, a member of FINRA/SPIC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Authorization for Phase 2 trials
$27M Raised to Date
4 Drugs in Pipeline
Powered by Leading Scientists from
Johns Hopkins
Harvard Medical
NYU
VA Hospital
UPENN
From $27M Raised To Phase 2 Trials — Follow Our Journey
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By clicking "Learn more", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms
Only 4 FDA-Approved Botanical
Drugs Exist — We’re Developing
the Next Ones
The demand for plant-based medicine is exploding, with 80% of the world relying on traditional medicine, but regulatory progress is in its infancy. AJNA targets high-need neurological conditions with therapies that are:
Clinically tested
Pharma-grade, not wellness-grade
FDA-aligned and scalable
By navigating the rigorous FDA review process, we’re working to return plant-based compounds to the heart of modern medicine — earning physician trust, enabling insurance coverage, and delivering regulated botanical drugs at scale.
Our Mission
Bring safe, plant-derived medicines to patients with Central Nervous System disorders — backed by decades of pharma and clinical expertise.
Back the Future of Medicine
Nature-Derived. Clinically Proven.
Our founding team helped create and scale Charlotte’s Web™, the world's Most Trusted Hemp Extract™, from startup to IPO and over $75M in annual revenue. That same leadership is now applying its deep expertise in botanical standardization, pharma operations, and regulatory strategy to develop a new generation of plant-based drugs. AJNA blends nature and science to deliver clinically validated, federally compliant therapeutics.
Back the Future of Medicine
Pipeline Highlights
4 Botanical Drug Candidates | received FDA authorization for Phase 2 trials
AJA001: DeFloria™ (Autism)
  • Cannabis-derived drug now advancing toward the initiation of Phase 2 trials.
  • Targets behavioral symptoms of ASD
AJA002: Novel Psilocybin (Anxiety)
  • Psilocybin-based drug in preclinical stage
  • Novel dosing formulation in development
AJA003: Novel Cannabinoid Formula (PTSD)
  • Multi-cannabinoid formula to serve thousands of people suffering from PTSD, including Veterans
AJA004: Novel Tryptamine Formula (Psychedelic Assisted Therapy)
  • Full-spectrum tryptamine formula derived from a unique and lesser-known botanical psychedelic species
  • Offering a different therapeutic experience than investigational new drugs currently in trials
AJA001: DeFloria™ (Autism)
  • Cannabis-derived drug now advancing toward the initiation of Phase 2 trials.
  • Targets behavioral symptoms of ASD
AJA002: Novel Psilocybin (Anxiety)
  • Psilocybin-based drug in preclinical stage
  • Novel dosing formulation in development
AJA003: Novel Cannabinoid Formula (PTSD)
  • Multi-cannabinoid formula to serve thousands of people suffering from PTSD, including Veterans
AJA004: Novel Tryptamine Formula (Psychedelic Assisted Therapy)
  • Full-spectrum tryptamine formula derived from a unique and lesser-known botanical psychedelic species
  • Offering a different therapeutic experience than investigational new drugs currently in trials
Back the Future of Medicine
Positioned at the
Crossroad of 3 Markets
The Business Research Company, The Business Research Company, Fortune Business Insights, Globe Newswire
Back the Future of Medicine
Top talent from NYU, Johns Hopkins, and Harvard | 13,500 sq.ft. DEA Schedule 1 Lab
Led by pharma veterans, AJNA’s leadership includes:
Meet Our Team
Joel Stanley
Chief Executive Officer
Joel Stanley is a leader in botanical drug innovation. While Chairman, he scaled CBD category leader Charlotte's Web™ from 0 to IPO with $75M in annual revenue.
Dr. Orrin Devinsky
Chief Medical Advisor
Director Comprehensive Epilepsy Center at NYU Langone, Lead Investigator for Epidiolex™, Professor at NYU Grossman School of Medicine.
BOB Judge
VP of Finance
CFO MuBiz, privately-held companies and family office.
Consultant to CW, CDB industry, Senior manager KPMG.
Scott Hansen
VP Operations + Quality
Development and QC Sandoz Pharmaceuticals, Director QC and R&D Charlotte's Web, VP QC and Regulatory Affairs Agricor/Botanacor.
Jesse Stanley
Board Member
Jesse Stanley is an original co-founder of Charlotte’s Web. He now serves as a co-founder of AJNA BioSciences. He has worked in alternative medicine for the last 15 years.
Invest In The Future Of Medicine
$27M raised to date 

Phase 2-ready therapy in a high-need market
Eco-conscious plant development based on sustainable practices
Early investment opportunity in disruptive biotech with an established infrastructure


THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

Terms

Overview

Price Per Share
$4.83
Valuation
$125.03M
Deadline1
July 28, 2025 at 11:59 AM PDT
Funding Goal2
$50K - $1M

Breakdown

Min Investment3
$497.49
Offering Type
Equity
Max Investment4
$999,998.37
SHARES OFFERED
Series A Preferred Stock
Min Number of Shares Offered
10,351
Max Number of Shares Offered
207,039

Exclusive Investor Perks

Early Bird 1
$525+

Invest $1,000+ within the first 2 weeks and receive 5% bonus shares

Invest
Early Bird 2
$1,000+

Invest $5,000+ within the first 2 weeks and receive 15% bonus shares

Invest
Early Bird 3
$5,000+

Invest $10,000+ within the first 2 weeks and receive 20% bonus shares

Invest
Early Bird 4
$10,000+

Invest $10,000+ within the first 2 weeks |
20% bonus shares

Invest
Early Bird 5
$25,000+

Invest $25,000+ within the first 2 weeks |
25% bonus shares

Invest
Early Bird 6
$50,000+

Invest $50,000+ within the first 2 weeks | 30% bonus shares

Invest
Flash Perk 1
Day 35-40

Invest $2,500+ between day 35 - 40 and receive 8% bonus shares

Invest
Flash Perk 2
Day 60-65

Invest $2,500+ between day 60 - 65 and receive 8% bonus shares

Invest
Early Bird 1
$1,000+

Receive 5% bonus shares

Invest
Early Bird 2
$2,500+

Receive 7% bonus shares

Invest
Early Bird 3
$5,000+

Access to exclusive investor webinar +
10% bonus shares

Invest
Early Bird 4
$10,000+

Conference call with the CEO + 15% bonus shares

Invest
Early Bird 5
$25,000+

Private virtual meeting with the CEO and the Principal Scientist + 20% bonus shares

Invest
Early Bird 6
$50,000+

Private lunch with the CEO and Science Team (Travel and Lodging Not Included) + 25% bonus shares

Invest
Venture Club

Venture Club Members 
earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into AJNA Biosciences.


Loyalty Bonus | Friends and family receive 5% bonus shares.Testing the Waters Reservations Page Bonus: All investors who reserve in the StartEngine

Testing the Waters Reservation Page will receive 5% bonus shares.

AJNA BioSciences will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Preferred Stock at $4.83 / share, you will receive 110 shares of Series A Preferred Stock, meaning you’ll own 110 shares for $483. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus in addition to the aforementioned bonus.

Time-Based

Early Bird 1
invest
$1,000+

Invest $1,000+ within the first 2 weeks and receive 5% bonus shares

Invest
Early Bird 2
invest
$5,000+

Invest $5,000+ within the first 2 weeks and receive 7% bonus shares

Invest
Early Bird 3
invest
$10,000

Invest $10,000 within the first 2 weeks and receive 10% bonus shares

Invest

Mid-Campaign (Flash Perks)

Flash Perk 1
invest
$5,000+

Invest $5,000+ between Day 35 - 40 and receive 7% bonus shares

Invest
Flash Perk 2
invest
$5,000+

Invest $5,000+ between Day 60 - 65 and receive 7% bonus shares

Invest

Amount-Based

Tier 1
invest
$1,000+

Invest $1,000+ and receive 2% bonus shares

Invest
Tier 2
invest
$5,000+

Invest $5,000+ and receive 6% bonus shares

Invest
Tier 3
invest
$10,000+

Invest $10,000+ and receive 8% bonus shares

Invest
Tier 4
invest
$50,000+

Invest $50,000 and receive 10% bonus shares

Invest

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

Crowdfunding investments made through a self-directed IRA cannot receive non-bonus share perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those non-bonus share perks because they would be receiving a benefit from their IRA account.

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into AJNA BioSciences

Loyalty Bonus
‍‍
As a previous investor or subscriber at AJNA BioSciences, you qualify for additional 20% bonus shares

The 10% StartEngine Venture Club Bonus

‍AJNA BioSciences will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common stock at $2.10/ share you will receive 110 shares of Common Stock, meaning you’ll own 110 shares for $210. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on either the amount invested or the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus in addition to the aforementioned bonus.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

Crowdfunding investments made through a self-directed IRA cannot receive non-bonus share perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those non-bonus share perks because they would be receiving a benefit from their IRA account.

Join the Discussion

Please check your email for the One Time Password. Didn't Receive an email? click Here
LEGAL DISCLAIMER
This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Invest
© 2025 AJNA Biosciences® All Rights Reserved Privacy Policy | Terms & Conditions